High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
A twice-spurned therapy that’s been seen as one of the FDA’s more controversial recent rejections is getting a new chance following the resignation of former commissioner Marty Makary.
Bristol Myers Squibb said Friday its drug, mezigdomide, lowered the risk of progression or death for multiple myeloma patients by over half.
Bristol-Myers Squibb Company (NYSE:BMY) is one of the 12 Most Undervalued Stocks to Invest In. On May 20, 2026, Bristol-Myers Squibb Company (NYSE:BMY) announced a strategic agreement with Anthropic to deploy Claude across its research, clinical development, manufacturing, commercial, and corporate functions. Bristol Myers Squibb said the collaboration moves its AI use beyond conversational tools […]
Schwab U.S. Dividend Equity ETF (NYSEARCA:SCHD) has become one of the most-owned dividend funds in the country, with $71.6 billion in assets and a 0.06% expense ratio. SCHD currently yields roughly 3.3% and has delivered a 20% year-to-date price return on top of income, outpacing the S&P 500. The key question is whether the distribution ... SCHD’s $71.6 Billion Portfolio Delivers 20% Gains Plus 3.3% Yield This Year
Iovance's commercial momentum and expanding Amtagvi pipeline make it appear better positioned than Agenus despite higher valuation.
LLY plans $3.83B in biotech buyouts to expand into vaccines and infectious diseases beyond obesity and diabetes.
BioNTech’s future rests entirely on the success of its pipeline, now that its pandemic-era glory days are firmly in the rearview mirror. Wall Street is betting the company’s next act in oncology will be worth the wait. UBS analyst David Dai moved off the sidelines Wednesday as he upgraded BioNTech stock to Buy from Neutral with a $135 price target, up from $117.
Kardigan plans to use the IPO funds to push its three in-licensed, mid-to-late-stage heart health therapies further down the clinical pipeline.
PFE is banking on new launches, Seagen assets and pipeline progress to counter a looming patent cliff through 2030.
Founded by former MyoKardia executives, the startup has in mid- to late-stage testing three medicines licensed from the likes of Sanofi, Ionis and Bristol Myers Squibb.
Bristol-Myers Squibb (NYSE:BMY) plans to present extensive new clinical data at the 2026 ASCO Annual Meeting. The company will share more than 60 scientific disclosures, including 19 oral presentations across oncology programs. Late-breaking Phase 3 data, including SUCCESSOR-2 for mezigdomide and izalontamab brengitecan, will be highlighted. The updates cover multiple myeloma, lymphoma, breast and lung cancers, and several emerging oncology mechanisms. For investors tracking NYSE:BMY, this...
With $14.2bn in projected revenue losses over six years, the Eliquis loss-of-exclusivity event is set to become one of the most consequential patent cliffs in pharmaceutical history — and a stark illustration of how quickly generic entry can dismantle even the industry's most entrenched brands.
AGEN advances BOT/BAL into phase III for MSS colorectal cancer as survival data and global access efforts shape its next growth phase.
Janux Therapeutics advances multiple oncology and immune therapy programs with key clinical updates, new studies and expanded partnerships with BMY and MRK.
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
The stocks in this article are all trading near their 52-week highs. This strength often reflects positive developments such as new product launches, favorable industry trends, or improved financial performance.
With an annual dividend yield of 4.25%, Bristol-Myers Squibb Company (NYSE:BMY) is included among the 12 Best Dividend Stocks to Invest in According to Hedge Funds. Bristol-Myers Squibb Company (NYSE:BMY) discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. Bristol-Myers Squibb Company (NYSE:BMY) announced on May 20 that it was partnering with Anthropic to deploy […]
The numbers don't tell the full story with this big pharma stock.
Tempus AI, Inc. (NASDAQ:TEM) is one of the 10 Best ARK Stocks to Buy Right Now. On May 14, Tempus AI, Inc. (NASDAQ:TEM) announced a collaboration with Bristol Myers Squibb to maximize clinical trials. The partnership will use multimodal data and AI to improve trial design and boost the probability of technical and regulatory success […]
As Kevin Warsh steps up to lead the Federal Reserve, the case for interest-rate cuts is disappearing. Plus, investment newsletter commentary on AI”s circular ecosystem, emerging markets, and SpaceX.
BMY stock rose after the company announced a strategic AI deal with Anthropic to deploy Claude across its workforce.
Retirees evaluating dividend funds tend to anchor on current yield, which is exactly why Vanguard Dividend Appreciation ETF (NYSEARCA:VIG) often gets overlooked. The fund pays a distribution yield of roughly 1.6%, which looks unimpressive next to higher-yielding alternatives. Morningstar analysts have repeatedly flagged VIG as a quiet winner for retirees precisely because of that misread. ... Vanguard’s VIG Quietly Returned 247% While Investors Chased Higher Yields
Even if a company is profitable, it doesn’t always mean it’s a great investment. Some struggle to maintain growth, face looming threats, or fail to reinvest wisely, limiting their future potential.
Contineum Therapeutics (NASDAQ:CTNM) President and Chief Executive Officer Carmine Stengone said the company remains focused on advancing PIPE-791 in idiopathic pulmonary fibrosis, while recent exploratory pain data may point to additional clinical opportunities for the LPA1 receptor antagonist. Sp
Bristol Myers Squibb (NYSE:BMY) is rolling out Anthropic's Claude enterprise AI across its global operations. The company is broadening its neuroscience focus after a US$14b acquisition, adding drug candidates for schizophrenia and Alzheimer's disease. These moves reflect a shift toward large scale AI use in pharma and a wider footprint beyond oncology. Bristol Myers Squibb is a large pharmaceutical company best known for its work in oncology and immunology. A full scale deployment of...
Agenus' shares slide after weak Q1 results, but BOT/BAL phase III progress, survival data and Zydus backing keep long-term growth hopes alive.
The Schwab U.S. Dividend Equity ETF (NYSEARCA:SCHD) has built its reputation on paying reliable, growing quarterly distributions to income investors, and the latest data confirms why holders trust the fund. SCHD paid $0.2569 per share on March 30, 2026, continuing an uninterrupted quarterly schedule that stretches back to 2011. For retirees and dividend-growth investors weighing ... Why retirees are banking on SCHD’s 15-year unbroken dividend streak
The market appears to be short-sighted.
BMS will roll out Claude to over 30,000 employees, targeting three main areas for near-term impact.
Bristol Myers' neuroscience heads are trying to make a name in brain drugs for a company best known for its cancer and cell therapy work.
We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.